These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 12393965

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Associations between maternal serum free beta human chorionic gonadotropin (β-hCG) levels and adverse pregnancy outcomes.
    Sirikunalai P, Wanapirak C, Sirichotiyakul S, Tongprasert F, Srisupundit K, Luewan S, Traisrisilp K, Tongsong T.
    J Obstet Gynaecol; 2016; 36(2):178-82. PubMed ID: 26368010
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ, Dickinson JE, O'Leary P, Bower C, Goldblatt J, Hewitt B, Murch A, Stock R.
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
    Borowski D, Czuba B, Cnota W, Hincz P, Czekierdowski A, Gajewska J, Jaczyńska R, Ceran A, Włoch A, Wyrwas D, Wiełgoś M, Szymusik I, Szaflik K, Sodowski K.
    Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
    [Abstract] [Full Text] [Related]

  • 9. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS, Huang YY, Hwa KY, Cheng CC, Lee FK.
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [Abstract] [Full Text] [Related]

  • 13. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [Abstract] [Full Text] [Related]

  • 14. Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss.
    Goetzl L, Krantz D, Simpson JL, Silver RK, Zachary JM, Pergament E, Platt LD, Mahoney MJ, Wapner RJ.
    Obstet Gynecol; 2004 Jul; 104(1):30-6. PubMed ID: 15228997
    [Abstract] [Full Text] [Related]

  • 15. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA, Lambert-Messerlian GM, Palomaki GE, Neveux LM, Malone FD, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Saade GR, Berkowitz RL, Dar P, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME, First and Second Trimester Evaluation of Risk (FASTER) Trial Research Consortium.
    Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
    [Abstract] [Full Text] [Related]

  • 16. Screening of maternal serum for fetal Down's syndrome in the first trimester.
    Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A.
    N Engl J Med; 1998 Apr 02; 338(14):955-61. PubMed ID: 9521983
    [Abstract] [Full Text] [Related]

  • 17. Ultrasound detection of placental insufficiency in women with elevated second trimester serum alpha-fetoprotein or human chorionic gonadotropin.
    Toal M, Chaddha V, Windrim R, Kingdom J.
    J Obstet Gynaecol Can; 2008 Mar 02; 30(3):198-206. PubMed ID: 18364097
    [Abstract] [Full Text] [Related]

  • 18. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 May 02; 31(5):493-502. PubMed ID: 18432600
    [Abstract] [Full Text] [Related]

  • 19. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO, Hoopmann M, Abele H, Alkier R, Lüthgens K.
    Ultrasound Obstet Gynecol; 2012 Nov 02; 40(5):530-5. PubMed ID: 22611005
    [Abstract] [Full Text] [Related]

  • 20. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome.
    Wax JR, Lopes AM, Benn PA, Lerer T, Steinfeld JD, Ingardia CJ.
    J Matern Fetal Med; 2000 Nov 02; 9(3):161-4. PubMed ID: 10914623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.